JNJ

NEW YORK STOCK EXCHANGE, INC. · Pharmaceuticals

Johnson & Johnson

Q: Is JNJ stock a good investment?

Johnson & Johnson offers defensive stability through diversified healthcare operations and a history of consistent dividend growth. The stock trades at a reasonable P/E with solid free cash flow generation. Risks include patent expirations on major drugs like Stelara and Remicade, litigation liabilities (talc, opioids), and pricing pressure from government healthcare reforms. Medical device sales can slow during elective surgery declines, impacting MedTech revenue growth.

Q: Who are Johnson & Johnson's main competitors?

Johnson & Johnson competes with Pfizer and Merck in pharmaceuticals, Medtronic and Abbott Laboratories in medical devices, Stryker in orthopedics and surgical equipment, and AbbVie in immunology. The competitive landscape varies by segment, with pharmaceutical competition driven by drug efficacy and device competition based on innovation and hospital relationships.

Q: Does Johnson & Johnson pay dividends?

Johnson & Johnson has increased its dividend for over 60 consecutive years, earning it Dividend King status—one of the longest dividend growth streaks in the market. The company maintains a sustainable payout ratio and prioritizes annual dividend increases as a core shareholder return strategy. JNJ's combination of yield and growth appeals to investors seeking reliable income with inflation protection.

Q: How much does JNJ stock cost right now?

JNJ is currently trading at $280.78, down 0.47% in today's session. Over the past 52 weeks, the stock has traded between a low of $185.12 and a high of $282.02. The current price represents 99% of its 52-week range, which helps investors gauge where the stock sits relative to its recent trading history.

Q: What is the analyst consensus for JNJ?

Among 30 analysts covering JNJ, the consensus rating is Buy — 21 rate it a buy, 9 hold, and 0 sell. The average price target sits at $299.55, implying 7% upside from the current price. Keep in mind that analyst targets reflect 12-month expectations and can shift quickly after earnings reports or major company events.

Q: Does Johnson & Johnson make money?

Johnson & Johnson generated $92.14B in revenue during fiscal year 2026, with $26.22B reaching the bottom line as net income. The net profit margin of 28.5% is strong by most industry standards.

Q: Is JNJ stock expensive based on earnings?

JNJ trades at a P/E ratio of 40.79 on trailing earnings of $6.59 per share. That's above the S&P 500 historical average, suggesting the market expects above-average earnings growth ahead. Comparing this multiple against Pharmaceuticals sector peers gives better context than the broad market alone, since P/E norms vary significantly across industries.

Q: Is JNJ stock going up or down?

JNJ has been on a strong uptrend over the past year and continues to show momentum. Returns by timeframe: +1.61% (1W), +6.46% (1M), +7.14% (3M), +23.85% (6M), +44.86% (1Y), +35.41% (YTD). Comparing these figures against the S&P 500 and sector benchmarks helps determine whether JNJ is outperforming or lagging the broader market.

S&P 500 Dow Jones Mega-Cap Stocks Blue Chip Stocks Pharmaceutical Stocks Healthcare Stocks Best Dividend Stocks Highest Dividend Yield

$280.78

-1.33 (-0.47%)

Day Range $279.19 — $283.25

52W Range $185.12 — $282.02

Performance

1D —

1W +1.61%

1M +6.46%

3M +7.14%

6M +23.85%

1Y +44.86%

YTD +35.41%

Open$282.00

Previous Close$282.11

Day High$283.25

Day Low$279.19

52W High$282.02

52W Low$185.12

Volume—

Avg Volume7.23M

Market Cap656.45B

P/E Ratio40.79

EPS$6.59

SectorPharmaceuticals

Technical Indicators

Full analysis →

SMA 50 $266.07 Above

SMA 200 $248.64 Above

RSI (14) 69.1 Neutral

Trend Golden Cross Bullish

Analyst Ratings

Buy

30 analysts

21 Buy 9 Hold 0 Sell

Price Target +6.7% upside

Current
$280.78

Target
$299.55

$223.02 $299.55 avg $400.15

Key Financials

	FY 2026	FY 2025	FY 2024
Revenue	92.14B	87.26B	81.19B
Net Income	26.22B	22.35B	16.19B
Profit Margin	28.5%	27.0%	19.9%
EBITDA	39.21B	35.28B	32.24B
Free Cash Flow	—	—	20.95B
Rev Growth	+5.6%	+5.6%	+12.0%
Debt/Equity	0.59	0.59	0.42

Dividend

Dividend Yield3.12%

Annual Dividend$5.14

Payout Ratio46.2%

Frequencyquarterly

Ex-DividendFeb 20, 2026

Pay DateMar 8, 2026

Recent Insider Activity

All Insiders →

Date	Insider	Type	Shares	Price	Value
Sep 4	Schmid Timothy	Exercise	36,517	$131.94	$4.82M
Sep 4	Schmid Timothy	Exercise	47,974	$151.41	$7.26M
Sep 4	Schmid Timothy	Sale	25,447	$274.74	$6.99M
Sep 4	Schmid Timothy	Exercise	0	$0.00	—
Aug 18	Taubert Jennifer L	Exercise	209,451	$115.67	$24.23M

About Johnson & Johnson

Johnson & Johnson, based in New Brunswick, New Jersey, is a diversified healthcare company operating in pharmaceuticals, consumer health products, and medical devices. The company develops and manufactures medications for various therapeutic areas including cardiovascular, immunology, and oncology. Johnson & Johnson is one of the world's largest healthcare companies with leading positions in prescription pharmaceuticals and consumer wellness. The company operates across multiple healthcare segments serving patients and consumers globally.

Pharmaceuticals Peers

Symbol	Name	Price	Change	P/E	Mkt Cap
LLY	Eli Lilly and Co.	$1,432.29	+1.44%	46.6	1.28T
MRK	Merck & Co. Inc.	$148.05	-0.48%	147.8	362.53B
PFE	Pfizer Inc.	$29.36	+0.44%	41.4	167.12B
BMY	Bristol-Myers Squibb Co	$62.80	+1.06%	13.8	127.96B
ZTS	Zoetis Inc	$82.46	+0.17%	12.8	33.59B
RPRX	Royalty Pharma Plc- Cl A	$69.45	+0.99%	47.5	38.68B

JNJ Frequently Asked Questions

What does Johnson & Johnson do?

Johnson & Johnson operates two primary segments following its 2023 consumer health spinoff: Innovative Medicine (prescription pharmaceuticals in oncology, immunology, and cardiovascular) and MedTech (surgical equipment, orthopedics, vision care). Revenue comes from patented drugs and medical devices sold to hospitals, clinics, and patients globally. The pharmaceutical division drives growth through high-margin specialty drugs, while MedTech provides stable cash flow from recurring device sales and consumables used in surgical procedures.

Is JNJ stock a good investment?

Johnson & Johnson offers defensive stability through diversified healthcare operations and a history of consistent dividend growth. The stock trades at a reasonable P/E with solid free cash flow generation. Risks include patent expirations on major drugs like Stelara and Remicade, litigation liabilities (talc, opioids), and pricing pressure from government healthcare reforms. Medical device sales can slow during elective surgery declines, impacting MedTech revenue growth.

Who are Johnson & Johnson's main competitors?

Johnson & Johnson competes with Pfizer and Merck in pharmaceuticals, Medtronic and Abbott Laboratories in medical devices, Stryker in orthopedics and surgical equipment, and AbbVie in immunology. The competitive landscape varies by segment, with pharmaceutical competition driven by drug efficacy and device competition based on innovation and hospital relationships.

Does Johnson & Johnson pay dividends?

Johnson & Johnson has increased its dividend for over 60 consecutive years, earning it Dividend King status—one of the longest dividend growth streaks in the market. The company maintains a sustainable payout ratio and prioritizes annual dividend increases as a core shareholder return strategy. JNJ's combination of yield and growth appeals to investors seeking reliable income with inflation protection.

How much does JNJ stock cost right now?

JNJ is currently trading at $280.78, down 0.47% in today's session. Over the past 52 weeks, the stock has traded between a low of $185.12 and a high of $282.02. The current price represents 99% of its 52-week range, which helps investors gauge where the stock sits relative to its recent trading history.

What is the analyst consensus for JNJ?

Among 30 analysts covering JNJ, the consensus rating is Buy — 21 rate it a buy, 9 hold, and 0 sell. The average price target sits at $299.55, implying 7% upside from the current price. Keep in mind that analyst targets reflect 12-month expectations and can shift quickly after earnings reports or major company events.

Does Johnson & Johnson make money?

Johnson & Johnson generated $92.14B in revenue during fiscal year 2026, with $26.22B reaching the bottom line as net income. The net profit margin of 28.5% is strong by most industry standards.

Is JNJ stock expensive based on earnings?

JNJ trades at a P/E ratio of 40.79 on trailing earnings of $6.59 per share. That's above the S&P 500 historical average, suggesting the market expects above-average earnings growth ahead. Comparing this multiple against Pharmaceuticals sector peers gives better context than the broad market alone, since P/E norms vary significantly across industries.

Is JNJ stock going up or down?

JNJ has been on a strong uptrend over the past year and continues to show momentum. Returns by timeframe: +1.61% (1W), +6.46% (1M), +7.14% (3M), +23.85% (6M), +44.86% (1Y), +35.41% (YTD). Comparing these figures against the S&P 500 and sector benchmarks helps determine whether JNJ is outperforming or lagging the broader market.